-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, EbT4sFkEm+shr6jxgmlFl7T63eIzvOR3f+LJvokSXR3FSCO4H2oSMVMSygob3XU3 DdplwupRIOvYKaO8N5e8pQ== 0001193125-03-039440.txt : 20030819 0001193125-03-039440.hdr.sgml : 20030819 20030819135333 ACCESSION NUMBER: 0001193125-03-039440 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20030819 ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20030819 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RITA MEDICAL SYSTEMS INC CENTRAL INDEX KEY: 0001056421 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 943199149 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30959 FILM NUMBER: 03855097 BUSINESS ADDRESS: STREET 1: 967 N SHORELINE BLVD CITY: MOUNTAIN VIEW STATE: CA ZIP: 94013 BUSINESS PHONE: 6503858500 MAIL ADDRESS: STREET 1: 967 NORTH SHORELINE BLVD CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 8-K 1 d8k.htm CURRENT REPORT ON FORM 8-K Current Report on Form 8-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 8-K

 

 

Current Report

 

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

 

August 19, 2003

Date of Report

(Date of earliest event reported)

 

 

RITA Medical Systems, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware

(State or other jurisdiction of incorporation)

 

 

000-30959   94-3199149
(Commission File Number)   (I.R.S. Employer Identification No.)

 

 

967 N. Shoreline Blvd.

Mountain View, CA 94043

(Address of principal executive offices, with zip code)

 

 

(650) 314-3400

(Registrant’s telephone number, including area code)


Item 9.    Regulation FD Disclosure.

 

On August 19, 2003, RITA Medical Systems, Inc., a Delaware corporation (“RITA”), announced it had appointed Wesley E. Johnson, Jr. and Joseph M. DeVivo to serve on its Board of Directors. A copy of RITA’s press release announcing these additions to the Company’s Board of Directors is attached as Exhibit 99.1 hereto and incorporated by reference herein.

 


SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

        RITA Medical Systems, Inc.
Date:  August 19, 2003       By:  

/S/    DONALD STEWART        


               

Donald Stewart,

Chief Financial Officer and

Vice President Finance and Administration


RITA MEDICAL SYSTEMS, INC.

 

INDEX TO EXHIBITS

 

Exhibit Number

  

Description


99.1

   Press Release of RITA Medical Systems, Inc. dated August 19, 2003.
EX-99.1 3 dex991.htm PRESS RELEASE DATED 08/18/2003 Press Release dated 08/18/2003

Exhibit 99.1

 

LOGO

 

NEWS RELEASE for August 19, 2003 at 7:30 AM EDT

 

Contact:    Allen & Caron Inc.    RITA Medical Systems, Inc.
     Matt Clawson (investors)    Don Stewart, Chief Financial Officer
     Len Hall (media)    650-314-3400
     949-474-4300    dstewart@ritamed.com
     matt@allencaron.com     
     len@allencaron.com     

 

RITA MEDICAL SYSTEMS APPOINTS WESLEY E. JOHNSON, JR.

AND JOSEPH M. DEVIVO TO BOARD

 

MOUNTAIN VIEW, CA (August 19, 2003) . . . RITA Medical Systems, Inc. (Nasdaq: RITA) today announced it has appointed senior medical industry executive Wesley E. Johnson, Jr., 45, to serve as a director on RITA’s Board of Directors and Chairman of the Board’s Audit Committee. In addition, Joseph M. DeVivo, 36, who recently was named RITA President and Chief Executive Officer, has been appointed to the Board. DeVivo and Johnson fill vacancies left by F. Thomas (Jay) Watkins, Managing Director of DeNovo Ventures, and Gordon Russell, retired General Partner at Sequoia Capital, who have retired from the Board to devote their time to other business interests. The Board currently consists of seven directors and there are no further vacancies.

 

Johnson has twenty years experience in the medical device industry, and, since May 1999, has been Vice President, Operations and Chief Financial Officer for Austin, TX-based Spinal Concepts, Inc. Recently, Johnson participated in the negotiation and sale of Spinal Concepts to Abbott Laboratories. He is also a former CFO of both Minneapolis-based Urologix Inc. and Dallas-based American Medical Electronics, Inc.

 

Chairman Vincent Bucci commented, “Wes has extensive experience managing medical device companies, particularly in areas such as strategic planning and operations, experience that will be called upon in his board duties and which will prove beneficial to the entire organization. He has served as chief financial officer at public companies, giving him a sound basis for financial governance, and his overall experience nicely complements that of the other board members.”

 

In addition to Johnson and DeVivo, the other five directors currently on the Board include: Vincent Bucci, Chairman of the Board and President of Health Policy Associates Inc.; Randy Lindholm, consultant to life sciences companies; Janet Effland, retired General Partner at Apax Partners, Inc.; Scott Halsted, General Partner and Principal at Morgan Stanley, Dean Witter Venture Partners; and John Gilbert, retired Vice Chairman of Keravision, Inc.

 

“On behalf of the Board and all of the RITA shareholders,” added Bucci, “I would like to thank fellow board member Randy Lindholm and our Chief Financial Officer Don Stewart for their tireless

MORE-MORE-MORE

RITA MEDICAL SYSTEMS APPOINTS WESLEY E. JOHNSON, JR.


AND JOSEPH M. DEVIVO TO BOARD

Page 2-2-2

 

 

work in overseeing the day-to-day operations of the Company during this interim period as well as leading the executive search process. Perhaps the most positive aspect of the past several months was the extraordinary progress the Company made in better understanding the challenges of today’s marketplace and improved ways to align the Company and its products to take advantage of our strengths in the future. A great deal has been accomplished these past several months and that is tribute to the quality and dedication of the entire Board.

 

“These board additions complete the transition activities and we are confident that the right team is in place at RITA,” said Bucci. “Looking forward, I believe this leadership will bring a new focus to our long-term goals, including expansion of our market share and reaching profitability.”

 

About RITA Medical Systems, Inc.

 

RITA Medical Systems develops, manufactures and markets innovative products for patients with solid cancerous or benign tumors. The proprietary RITA system uses radiofrequency energy to heat tissue to a high enough temperature to ablate it or cause cell death. While the Company’s current focus is on liver cancer and metastatic bone cancer, the Company believes that its minimally invasive technology may in the future be applied to other types of tumors, including tumors of the lung, breast, uterus, prostate and kidney. The Company has received regulatory clearance in major markets worldwide, including the United States. In March 2000, RITA became the first radiofrequency ablation company to receive specific FDA clearance for unresectable liver lesions in addition to its previous general FDA clearance for the ablation of soft tissue. In October 2002, RITA again became the first company to receive specific FDA clearance, this time, for the palliation of pain associated with metastatic lesions involving bone. The Company has sold over 45,000 of its disposable devices throughout the world.

 

Except for the historical information contained in this news release, the statements in this news release are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. Information regarding these risks are included in the Company’s filings with the Securities and Exchange Commission.

 

RITA and StarBurst are trademarks of RITA Medical Systems, Inc.

 

# # # #

GRAPHIC 4 g25667g27u28.jpg GRAPHIC begin 644 g25667g27u28.jpg M_]C_X``02D9)1@`!`@$`8`!@``#_[0IV4&AO=&]S:&]P(#,N,``X0DE-`^T` M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0`` M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`& M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4` M```!`"T````&```````!.$))30/X``````!P``#_____________________ M________`^@`````_____________________________P/H`````/______ M______________________\#Z`````#_____________________________ M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0` M````.$))300:``````!M````!@``````````````0````2`````&`&<`,@`W M`'4`,@`X`````0`````````````````````````!``````````````$@```` M0``````````````````````````````````````````````X0DE-!!$````` M``$!`#A"24T$%```````!`````(X0DE-!`P`````!]D````!````<````!D` M``%0```@T```![T`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4` M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P, M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X. M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P, M#`P,#`S_P``1"``9`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$` M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@) M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D M%5+!8C,T)E\K.$P]-U MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$` M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D M8N%R@I)#4Q5C+RLX3#TW7C\T:4 MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B7I[?'_]H`#`,!``(1 M`Q$`/P#&;CM8US[ZS2QH^EDVBD"?H_HQ7]HN_J4L5RCI[;?3)J%8/N+-A8XU MG7UF_:W7W^A6WWV9N17T_!J_[EH6/Z-=+\UA&'C0YK^IY`%V198WW65=-QY% M3,AWT?5_[2_X;J='\VM1KGXE+[2&8=AV66_:W&T8X=^DQL_KEFUS^J]9NGU> MD])KK]/I_P"CR;,=626W(EL9O4*>AX_V#H]`NZ_E-(:ZNN74,(/IMKJCU79E ME;?5VW-]9E?Z?)_1^G2O1O2%E#6/+OHB2U[FNF/])6YKO^DO'2^JPOSNI]8HR\O*NJPKO3QVF^QNUN_(9J:GU[_;37]--U#J?4NC_6;# MP,/-?GTY;FBW!MVV/J#G-;N;:QOVAOZ-[KF>L[_!_I?^#!]6<#&ZAU3ZQ57. M>W]8(:^FQU;V[K2?>ZK/L&ZQ MW_&6?^V_]%;U_8U!?".FOS?5["ZAES-CR\#Q8]S#_G5.8Y3?=;8^R&WVLK8USG.KII92^KV55EK/O:W:W=:W;^BLKW_0;_`#B[!!??K^"0V*"`)1'F]!T[IU^#DY).5;DXUVQU-=[S8ZMPWBUK7O]WIO_`$;E ME_6K,ZED5W=*Z(Y[AS/^U>597^CJ_T%-W^DK6QU7J- M?3<)^2YOJ62*Z*08=;<\^GCX[/Y5UKFL_D?SGT%G]-Z1UO$J>]V;1]IRGG(R MW&ASYM>!N8RPY-?Z&AC648_L_F:TAW21IPC\&Q]7.MU=;Z77EB&W#V9%;3]& MP<_V+&_I:_\`@WK47#/]3ZG_`%B9D76,=T[JTB_8WTF5O#@38*B^W:RGU/4^ MG_,VW_Z%B[@$$`@R#J"$B$PD2*/S#=__T+&!@?9:Z_K!]8;@W*+6#IV+8&UF MFMKFBO)]']'5CMI:/U3&93Z=;_T_I_:?YK-RNK,>YME=[:GU.M--A?6US18Y MWJNI^TN>_%LLW?I+*L._J.4_]/D=3R%Z!UC_`)1_ZVS\KU7J_@IQOK7[/HV1 M=ZUX?NU_5?,[LW&8;'T74T.AWZ5FZ^TG_2?:,J'/M_X1GV9>SY;L<8#79%;; MZIK#FOB/L5_T'?`KH,C^CN^`_*FY>BS-M&_%S,7&Z.,J@8O3 M<>KU&FP6MK:UP:UQ],CTJC]/;O\`TEE2L67XN9B.;FX]=M;2?4J=MM9+6?:6 MEOJM:U_M+?S?98E?_P`HX'PL_P"I4^E?T&C^L_\`ZJQ1:L&E=&M5B=)8VFC[ M!BL;NS8+&"ME;3,2UGJ,:B M],_Y/Q_ZC/\`JD'%_P"2LS^M?_WY'57I\$]EM64*ZK\=MU-C/5),.8"SZ;7> MJUGN:YS-F_\`X3^;]-5,3$Z8QV+9C=-Q*K+'EKW,:UCJW5R^&[:6N>YNS_@E MH87]&QO^);^1B!TK^@8?P/\`WY#51J]::>;;TVZJO,S^G47O<'[#8T.<`QAL MK:UV356[]([]&W9^^M'&MJKNLPJJV4UT@>FUI`D'W/VUM&UOO?\`O?YGZ/U* M.!_1'?\`'O\`RM5C_M=E_P!;%_ZI)6EK=1Q.E.>Z[*P:GN<^MCW0]PH_ M/:YWL:IX;\2DUX^'331CO:'@5EK!+F[V^G2QHWLV,_G/_,]EJWGYL_ZI5#_3 M:O\`PH_\M:6JM+Z6_P#_V0`X0DE-!"$``````%4````!`0````\`00!D`&\` M8@!E`"``4`!H`&\`=`!O`',`:`!O`'`````3`$$`9`!O`&(`90`@`%``:`!O M`'0`;P!S`&@`;P!P`"``-@`N`#`````!`#A"24T$!@``````!P`(``$``0$` M_^X`#D%D;V)E`&1``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$! M`0$!`0$!`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#`P,#`P,#_\``$0@`0`$@`P$1``(1`0,1`?_=``0`)/_$`-$` M```&`P$!`0`````````````&!P@)"@0%"P(#`0$``00#`0`````````````` M``0%!@W.#F!T5)RDC/4);569Y=8&776)U?7&!H1``$" M!`,$!`D&"P<$`P````$"`P`1!`4A,1)!46$&<8$B$Y&AL3)"4F)R%,'1(S,T M!_""DJ*RTE-S%18VX<)#D[,D5.)C@Z/351?_V@`,`P$``A$#$0`_`(8?,_\` MPC?\H?\`?ZZ3[QSUSX3'5^E(]$0I='QG9--366S?*M+OZ+8/)RO2J/:+2@V) MYE3\W*T'&/DFZ8'.4!,<2E`1#N/6AZN9IR`_6)03ZRP/*82O5M!32%15-()] M921Y3!O8\LF4:%7.CD"VAQSW&EJ'A"=/7.7&/H M7*\OC6JCJR6&\W/[4SO]GZ!2ZM5U6S=,A17>.RQ2^V/48]N;O\BYT$TB$#R,)0`>M3 M]96,`+?J6&6]ZEJ..['NQ&BIJ:NG2'*ERDIVMZE%7@GH$^&,.MRGC+39N584 M@,NS*"UJG_VTJGLBRSP$]9V,,HN+U/4M>UFE:G[(^/O M![BFG6SXC%S.E--.OTO;J(PD<@<>UE[>Y6?I.6ZZ^7 M0J%80WH229I"G$`E4\9E)("3D#CCE/)U#(@\(=JM)V^T2#1UE6YQN5LD(LS= MU%R.40N@IOY3YW"A9(SV1L$*Z:I?"HFF*!`$O9,3>7//'V:<$M3AL_M>D8K=H>VUXUIJ%LA< MJ1C2R$:E).HMVRE(EY(+'C)F/<-BF5336];7-4Y2)V=<8L=ZYTOZGQ15=.$MZ=16D#SIRE)))R,20.*=[K8UJ9XTUW M@S8G39$R@1#FL:/'DD%"IC^H*\1K+0"*G-^@(G0)Y=O(2E[]-X5:R<4/`=(B M6*:YY2V--5;E+`]5P$]("&&[/[5/9CP]GXV&Y2<5,@;1LBM\459:^A<&5 M=LPD*9=5"&NL=>+E63R)6I?,S4R17B!.QE4"@/2QJWT%2":>H5/<93'5(&(Y M7`4%J3/AGO$/RX9>XGCERNGXK.9]J_Q/69A1HRA M:W;Y!D\K=NE71DD$XJHV]`K1!S+N':@)H,GK=DY>PL;88UM+L6D]+2]DB40F$V;L@.$4&YTD5O(H*J`'D+&^NA;<4ANF4 M0"1,J(_`19EKI^:*JD8J:V\MMJ<2%:4LI)`(F`298[P!@<)F%DYQ[5?N+W"G M4=>K\Y&26DT"K4YNRL,E`MPC)6S3%KJM27E%ZXFNJV;HR+J845!L50R:'F`` M82E[]::1I%15--J3]&HG#A(G.'"_UU3:K#5U;;P-6VA,E$"145)3/3EC.\#E56FMXS^!R&O4&0$?PF[:/3(RHPDV0OT%S`MC*O[#-QWD`E!XU M8JLQ.4Q`5$Y3`#H^S::=6A>HKW`D^&(1:[AS_=VA44Q:33G)2T)2#T8%1'$" M7&'GHT/WD*%$5-KX,-Q`W8"J0M\,)@[`/D`HY4OM"]F?$G:;+AFB7?!)RUU=G7GS^1I5!6D*\ MLE9(&/L+$C1U.LJ[)**),I$A50.T3`JH&`HF*`&%PIZ"@J64O(:4$F>9QP,M M\1&[O>MU16LJ>;"9E*!+M)"A*:0#547!13,#H3B'?R*7I+4MVRE=+2V' M"J4\#OZX?;-5\ZWNB374URI4M%1$E(QPSR01XX7JP5;WKP[)5U&:5PMM2Z9? M(L;"1M@:/5Q\3CX(J66CP$@1#=M M/U>TW.*K4A)5*W14D_AI5L4KXQ0>IS,A).9P( M$\0886>8^;*2]VZVWB2$NO(21H3VDJ4$G2H8'.4P<(M#]1^+;@=$$:J=G8:K MPDQ9;'*,82OUZ+D)R=F91RDSC8B'BFBKZ2DY!XN8B+5DQ9('554.(%(0HB(] M@ZR`5$)2)J,>''$--K==6$MI!))P``Q))V`"*KU`]W%LD_8"O/66<68<.;1+ M_NUC*R_:MV:51K2CU)G!Z\],*)7R,V,@4'\J1114$HMRLW(0QT$#!('+2D4< MDC_<@3GOX?-QBI*;GUY?,1<=&(F,H]]$$#H@@=$$#H@ MC__0C74Y*ZZA($E:U+UG.9-'Z-I/(\XS?(I9J`"02_#-9K4ZM,_(44P$%#.# M*]_KY=Q$>NA?@:8@I6A2TG8M2UCP*41'4`M=&1)Q"W!N<6M8\"E$>*/M'QW) M_E5/.DV2>W<@I^+:"\DG*SBZZ2ZA(Q/L"DC,R3Q66+!Q#<.PJ.72J+=(/J8Y M0^O0I5!;D`J+3#9,AYJ`3N`PF>`C"U6JU-@J[AA&SS43X`83/`8P:AX\4NE- M!?[;R!S.I.BI%7+0MM^TAV3L!SH%-0),0VDS*A4JXYV)::O\`+'>()F.L_K^*Y+^S=;`B"91540GG=J8) MD`PJE,0O<-3X?#9>K[BEBG3GHDD=!<7,]:0@[H3OIK$,J?NMW13TPS#4DB6X MN+FK\D(.Z'AS-,>U\L1FO,7>;5<+'.V!LA7_`%P\&OV4^Z_;%:03:,X&^QF9 M12.#9A/.'?=LLQC8^=M(&4`!;$5\A*V)=UZG[90I0A*<:JHGYLLTE7TBQMF2 ME'&4,J'4+#E19:%"&0#JK*G4>SO1K/>+&T$E*.)B7#CWBDK6I>LX;8,TI%$N M5MB&,\S]=_'V7=,8*NTT&Y2MM.]F?($JDO>;?6&[1TD=6MO)!PA,G62:-XQR M995J2,UU8AQ#E6V^I;23+XEP8E7J4K>"4GVP!IS*A(&(E<*P.HNYU'(5BL MWT+C%XE,;Q6ULQNP"/B4,*TT!,/;\A0$?R]/?-9E8+CT)_33#_SW_2]R MZ6O]5$=#CJD(Y]@=$$51OZQ?_E1XR?T!T'_&*O\`4BLGU3_O"*@^\S[9:OW: M_P!(0:OZN5_/?*S_`.%Y+_*[]UKO>=/^-\D*ONRRN_\`X_[\6C^F&+5AJ7.3 M.*-J7$?D)6="9QB\"WR>]V5"0DT45"5JH#I!.(ZX:+_34]79KDU4@=UW*U3/HE*20K@4D3CG M=(K*MU4EVZJB"Z"A%45D3F25153,!TU4E""4Z:B9P`2F`0$!#N'4VV&<+VY=/[A:L4SBS$E(56,76FW8CV$SF;\@ M=G-]`,981```>H15(2BI?0CS0L^7Y(Z8L;[U39[745!)?6P@J)S)*1B>G/KA MRO6B'2,&3_FV0_O%W_)U.O2?.3TQK=^J<]T^2.8L;]$?[`_VNIY'*VR.FE2T MDT*=4T$B@1)&M0221`[B!$TXMJ0A0$1$1`I0`/KU`U>-R/+7`+9@SNU+TV.N,M2'MQ=T)6I!)E/!*TJ(S&X=#?^FB+`?HE_U"(C_.MI'\IB^F2[_;%> MZ(LKD#^G6OWJ_+$RG39$UAJG*3BU`NY9.M6?#=TSO:JK8BQA9)R!Z9 M,(OY:M&*#IDHFPLS-(J:@@H)4UT4%A(<4@**BGJ"QWHE-*T%)'3MZH9[O:6[ MH*!17I=IZA#J3*?FF93^,/`9'9#J^D\/$#H@BOQ[AN2UST&T4+UO<=EE934= MFEJZEIP13HR9X^!EU@<05*E';8QE(IK+($+,31S@4J,&B05>[9RH`O-L80A* MZY_!M`,NG?QW#C%<\ZW1^I=I^5[89U;Y&N6P'))ED#YR]R!C@8@&]@O!6U\% M-7A*5(RR]NIENJT9/4^\BQ^Q1F'K=HV9W"*6;D%1)F^A;#\@D1\SG_#W#50Q MA,H;L\T58BL;*P)*!Q'D\(\Q8/G:C@N1U+ MVG%$J/68V)I+5:TN52DMMR':<6>U+VG%$J/68<1_^I6-<=T"2O-_7#Q%O2[F M#BO@$E6[MNR2Y?MSE9:9:U3R6:XF8`6_7M7RLG/(E`>\8!P\>D7\2JJTZ;13 MS:_;.`I;Z4)P4YTB23ZT-QO%=<3HL=%-G]NZ"EKI0G!;G2))/K0ON*V3E!S` M7G<&X+9?4N'_`!W8QQOWP7"H2DE7&+&E))/E7]@Y-\F9HZEUMK$D69RHI$@Z M18.$4S@VBA!,P@BJT6^UA-9=ZA=56S^C2H`G5N::'9!G+M2)&U4(*YNU6<(K M[]5*K+B3V$J`/:V!ED=E./I2GO5#I..#.K430R<1_4Y#-=FY.SS)S%;7[$;I M!)#6,MK2A21MPE,1152>MZ726`+J(!.*D7>RRARI,@>J*L5"MUP4X\Q_$N9% M=U;TF;=,DXK.8#GK*VZ):ZJ7&1>N.8W,=](J2-^Y,7IY]R2TP\3;C/'K] MQGBCIVNBLLFX.F^2,HDDJX;KNG3/` M@!*ZRV6HN-0S>KTP$)0)4].!)#*?1)3EJVR(P.)`(`#`>)7![7^6\A.2U>-" M9YC%#25D-9Y!:2\+7,FS6':)(N7ZLM87ID&TC.$9N"'1C&QS.3@H4ZGPM_-< MCSTK2$EME![")J2)J/I+ MD2-PF9;A`>:*"[55CK+Q>WM"TZ.[80>PWJ<2F:SZ2Y$C:!/J%O+JL8J:!T01 M5&_K%_\`E1XR?T!T'_&&`ZD5D^K?]X>2*@^\S[7:OW:_TA",^D[EQQWXJRG( M1QOND-,]1ND?G2-9.Z@+;.A**PCBX'E"D"K0$X9M]H220$?F!,#?)^;Y=C=M MEUI7Z@LEEO5*<\N&^$O(EZM=H%R%QJPT5E&F849RU3\T'*8B;>W^[?UZ5EDZ M<16HVJ^.VZ1E$XFHYC>DGCPX)^94&SNX0M2A054'L4/D=ID`P_G&`.X]-:;5 M6JS;`'$CY)Q.'N>^6VDDHJUN*W)0ORJ"1XXB>Y1\_N7WLGIT]D'#CC=K$?B, MJ^2@;Q9HF"D)N?LH@5!V>J6>TQ!#TRDQ#I)P@H[8@^46C$#Y0,S^&V(?=N8KUS0PY16.UO"@)DI0$RKV5*'90#,$B-Y%3'JQ--INS6,[1=!-EC^[VH4ZW47M24L@S[I)FI7 M!2A@`=H229;1G%JE@P8Q3%E%QC-K'1L:T;,(^/8MTFC)BQ9HD;M&;-J@1-!L MU;-TRD33(4I"$*````'4?)))).,6XE*4)2E*0$@2`&0`C+ZQ&8P9/^;9#^\7 M?\G4Z])\Y/3&MWZISW3Y(YBIOT3?V!_@_@ZGD?ZGN'0W_I(BP)Z)/]0B(_SK:1_*8OIDN_VQ7NB+)Y`_IUK]ZORQ,I MTV1-H'1!`Z((:GS1Y45'AWQ^N>RV8[-U)L6PPU!K+E?X5;C?Y1!P%=KZ)2'( MX.V%5$[I\=+N=O'-G"P`/Q]A44M.JI>0TG+:=PVPT7R[LV2W/USTBH8(3ZRS MYJ?E.Y()V1%OZ;^+5NEU[I[">09%YC8-\>SDC0W$RV(5U'U.P/!.!#Q32@4R@CV;N_'I?1$P5(X\1.@GV1T-2:5]*Y]@X*Z/[,XD?,UD1?+6 M[3`#XI/:;.Y8&4]RLCTSV"*07'[:-(X>YY;;7#"SU.4*YBEI! MDUH>9A;NT%$Q'N4>H6ZVIEQ;2Q):3*.CZ&L8 MN%)3UM,J;#B0H=>P\0<"-A!$*7UXA5`Z(('1!'__TFXDX<9K@3-.=YSZW^[V MW\4 MJ*PZ;12]XC]JN:6OQ?2<_%&GVHZ,_C53<26[%2%:#_C.`I9'NX:G#[HT^U&B MN7.RPP=;DLSXE4.#XBY;)-EHN;7SM_(/MNT:+,JN;X]4W>0,6\3K9T1FK.VM::BY.FIJ1B-0'=I/L-^:/>.I7M1L9L#;CJ*J[U*JN MI!F->#2#[#0[(X$S5QA5,!X"5^+S>.Y6<]+I)\>>-#L`?TRMIMT_W]\C5?MD MG[:)QZFR1/N"Q,JDX2$9UZF5D1!8JY>[;S=))ZV\K4^JVV=H/W#(G_#:V36H M;1ZHQGAG@4MPYA<54&U6!@5%RR4?\)KBM0PF/5&.S/"%=1U#?_93;ZKP3X/9 M8PX[\58IR1T.9U-5ZS@T*VQ>-$WNN+M4%^Y'TSG,^@TG)(SE+9.9`PA'\)05$:*"=CWRQIMU M6,S4*C,L5EQ;9:V,LHU$&JGV[I#Y$$%%VZ[IU(XMMMJKA5(O=Z1)T8LM')H; M"0?3VXY9F1`"<6FU5EWK$/U377Z:AL`GUXB$`Y:\\M$Y,Q\)F-5U"UEZX+\]U6*CP'JIW`< M)SE#A:+!3VU3E6\XI^Z.>>\O%1G*83ZJ=P&S;E#X_17QOVV5YOX+R#)GTW'X MO5WFF-7.BSQ4*]6YF4DLET&`;P=-=S2S$;S.IOGH&79Q!7J[5LBLNN5-%%0Y M6KFZOI$6FMHR\#5*2GLC$@:DF:I>:.*I`X`8F&+GNY40L==;OB4FM46SH&)` M#B#-4IZ1(8%4IF0&)$7RNJ;BBH'1!%4;^L7_`.5'C)_0'0?\88#J163ZM_WA MY(J#[S/M=J_=K_2$&'^KHM&KJ:Y5`Z;-W($B\F\`7136`@B[OOD)?D*;Q\NP M=^W\'7B]D@T\CO\`DA1]VB$+3=]:`<6\Q/UXE)]C/K'SOFK4C62JI0U!Y`UF M/.G5;H1H1K&6EJ@FH9O3[\#)LHNZB#J&_N5Z0BCN-4'N0%$3*(*(**O72KDJ M:F3F-W$?AC$JYEY5I;XQWC*4MW%`[*L@KV5R&6XYIZ)@U3L)WOD[ZPN1LTS6 MAY:LS\#)HP>KY#:#+H0%SB$3"JBFZ!`RK9;Y&CG[J%FV8JD`BQ5D3K-5CD6D M+S5/<&$XS2<01L_#:#Y8J*WW&Z\IW1U);*74G2XVKS5#9XL4*&^8F"0;LO%# MEGD7,7*XW4H@"J) MS%$>T5J*=VF<+;@Z#L(WB+UM%XHKW2(JZ-R8R4D^Z/)!AZQ&R!T00.B"*-'NQ_VB>P_T>RG M_1C5>I=:OL+/7^D8H#GG^I[AT-_Z2(L!^B3_`%"(C_.MI'\IB^F2[_;%>Z(L MGD#^G6OWJ_+$RG39$V@=$$>3&*0ICG,4A"%$QC&$"E*4H=S&,8>P`4`#N(CT M014?Y5VK;?;AS`EJ-QKK$5H.%<8!*=FRG;.K6J)=3I6!NQG[+)3K5^V.)KZN M@=G%?9K).S0C07"0I'%SCBCRY@[3-\MMTQ/,\UC=`GXJ)M?[FYY>>K2=P<,5BEL< MRQ7D)1W"KVC[(`<.#J`@YD1\C=EW'ZQYH*FE*13,NJ40,-662\"%%9Z/DGN]+K0*E`[2<%=& M_J\G1#S]W]^^'?59:ES2*XBL-:/D+)Q[XY3?@04U=@D62@)7[1(-T M4Y30R"@MVRI?(?C$&SXT9[^X\PS32%=+9]KF3KH]B?F)/K9GPB(A\1=>:3IH MBY1V(YN>:ZZ/^WZJ3ZVT;\1#3ZG`,I@!,<89[US^:N;7$M-)Q8 M95DV,P2GTG#F!(F>8!`"4@-+<5_5@<[>M*4/F+S_`(PHIKVLR1;%QJXO65NH M80&LHN"-QTS5:X^3*8'1R%;QSM+M_8?K`NELI]')UT<<]"#NS M(WB4E>B[A!W;1O&,-#AL7Y=<\K-9^1.G6R8$OW M*/D':$:+D%>$C@C.D8X[5*(&]4/*ZZT6!IFW4K4W@.PRTG4X>,AOQFM1`S),&@ MF@<*.+1S)Y-34>:>QLDQ1_>EME<>07&VO2!FZI%']#Q!PNTLFCF:*K=DW%P. M@Q.=,%`BA*`&-J#-UN$C4NFDI3Z#9FZ?>QXZZS@8Y\NDSK%2BQPK3/" M$I-0BTF-6ID"@4A2ILHMFU:D`H=B=(.8*&DH>7+DW2L)0"$DG:HZTXJ4<5'B M23#1S9;:&V\I7)JBIDMI):F?24>]1BI1F5'B28OH=4U%%P.B"*G?]8L?-%-? MXVQI%TS/FF;71\Y;`8!61:2-GCT&2YR`/D5-RM%N"D'\@BD;M^0>I%9!]$^= MFH>2*?\`O+4DUMK2#V@TH]14)>0^"##_`%_Y0Z\WM/9IU<2/)&[[LW0'KLP.<)9YIB;;NHCV^=PC5K:5!)1 MS+4UX]6$YB`!EV2IS+-_J95-991UKE(N8Q:.8^4<8C7,?+5)S!3R5)%<@=AS M^ZK>DGK&8V@U!Z/>^57JVY//TP9/:7?JJZ+&VVH2_P!RXI>E5!1R(IBGJ+QRE=5`@MO MH/:2?-<3/\Y)]$C$9B1BY)PJ]@.$\V:>V?T::;U[2&+(%;CD<\^:IV^OKH@D M1X]CD/)/]I:L998OP230ID_$Y"+D;K^2!(S54;U*HA8FC8K8?F/"+ML7,=OO MK(53N!-4!VFR>TG>1ZR=RAAOD<(?/TDA_C16F4CX.LV*:EWB$?%0\%+RDF_= M*D1:L8^/CW#MZ\OQ\@S<(*"!1.BLW<%,4>P=RB'4$<&EQ:=Q,=2TCB7:6F=21I4VDCH( M!@]]>(40.B"!T011:]TDDPD?8IMH,'2#L(^+R^->&;J%5(@^;9?41CY3@ MRZBVKA)1[6=HOL9)MRG[K-UWL;5IUN*I!`HE*LSE2"40[E'L/U[@(`RWA)%7 M/84CY1%C?=ZZE=@*`>TA]8/6$J\AB:[IKB=0.B"('?=3S\98KF$AQAR^P-SZ M_JT2=C>W$:Y35>4#-)9L=.00<'14,:.L=W:*?;-TS@"J<8LLX#XS':J&=[71 MEUP5#B?HDG#B?F'EZXK[GKF--!2*M5(Y_OGDR5(XH0<^A2A@!GI).XP_'UT< M/8;AGQMJ]#.V0/H]H2:7+7)D@IK*/;K)L4/FAT'1"AYPU2;`6/:`7L0_Q*+^ M(*.%!%'6U)JGU+G]&,$]']N<2#EFRMV.ULT\A\4J2G#O41ET)\T=$\R8?CTD MB0P.B"$QVC(J7O657O'M"CPD:AH-=?UZ72*5$730'1`,REXQ1PDNDVFH*131 M>L5Q(84':":@!W*'6QIU3+B'4'M),X25U$Q<:2HHJE,V'$D'Y".(,B#L(!CG MAZ]GUPXQ;_>X@1;D3+;(V.`_P`@56V^`N&JA`,D M@L*K43"H@81B=;2*I'BF1[L^:>&[I']L7WRS?F;[;T.Z@*U``<3N5ZP'JJS& M[$9B)".D<2.!T01__]0LZ/SER3C!1[!QZ]9T;.5%C.-3PVJ\RK.S+';_`+$D M4_B\8TIUX)/LFSAVL@DJU:M2M)'LF10X-W`KG6NMBT5-P=16W]06H8H8&+:/ M>V+6-YF.D2ET!36*LNE0BX\S*2LI,T4Z<6F]Q5L6H;29CI$H8UQ8XL;+S.V: M$Q_((1:9L,TL,C8['(?=!7*57"NDB3%UNLN1)P:/A8X7`"8P@=PZ<'3;MR+. M5DDCNURN5+:J5=35+D@8`#-1V)2-_B`Q.$/MUNM%9:)=75K`;2))2,U'8E(W MGP`8F0$6'$S&YD_#W'(&QL16B['DG'X[1 M11]>H@%#.(Y!E#G.T<&*=FFNO]RNI+0KOWG*UJON5.7KNK&GI4X]T#B%N;$G M(DJQ&<@1V:Z-6]47!FYW6G+]W5]FHTXAH'S5N^JNK"8G.8G#PIBGIZINX("&Q.9]M6&V>V&4_M1P@XK*^%&KZ/.;:8P3)FNFDQ$K5^*5 M)A=BU=KC@ZOX2D/HI(+Q&X MKQ2C\6:AZT/0:OMV$ZASX"B/HH(+Y'M+Q2W/7Q,M3BSX8*2N-X7GA MT1U_D'%66434\7U"XWQ(Z=*,S^!CD0D],G7%3R)))40#NY@I*TE3\P[IB8#D M)L^)JWI_#492G8ITZ/S`"OJ4$=._O\`K7V37'-&D2(1JD6-,S&MD=F:D36. MUK9W_P!N)T?O!(HK\C#S/3U)L=>[45A,@GLH`2CSTYSU+/6J4]D1?G*EKARY M<'ZRX%I:I<52GC+*+W'5.Q1T(+K6+6?399A(PG(C$RMSE[>+DU3.7*XRSX]WS"\2I)3XUP1`S=R@D":1.R8'\CFVMN)0"%,I M5CMG\A$(*NB>JE`MW)]A.F1".[D>,UMK(.S`CPQ&MHOH\X[Z[:G]YU'?>6]_ MM\F5)-[8[9HU$FY55!N42-6A73[+ECH,6:8^"*"?@BB3\TA2E^G3@B[/-IT- MLMI3P!^>(K5545=RK''CM4M!/1BC+A&1F?I'P#&+4VO&3\@^7.=VUH M@LT2GZEH]$A9$[)P9,SF/P=8M MO"NJU?J:YC8B]02!U`,_B6DM(Q,RS?BJ0I%R$4*IIJMZE4 M2T<#F#D89+UR_;K\TANM00M)[*TR"T[P"0<#M!!&W.1B/R(]`_$NORC";@== MY10DU%NDGL9+Q%[H$9*1KQ`P'0=L)!EEB#MFZ1.'"$3!Z(?IE_#NQ9:]179\R^9%T8(L) M1B,+I>@T"],532$.^BFKT[R:RU:=*\A5WA'K42/"D%VW2^8JJ7R)'1N527!] ME:!GL!'R[:7-&>J+099F.7+]#MW7RHG#Z"4>O; M5:&5:T4C6K?(GRJ,:*WEU=P:4Q57RM+)$B`IM((W'0TF8X&&:'-6NU6-;D:15;<7[++)!PS-,3"1G!Q=KQN<90C0HF$02:$13[C^3I*[7 M=\2IRE:*M\B#X08>J+EHVYM+5)?*Y+21()*FU)`W`*;4!U")"8&-7A8.%AW4 MS*6)U$Q,=&N;!."P&:G5V#-%JM,S`Q3"+BQE)-1(5W'VS5LA\IS?&DF3L0$1 M,R2!(;HDB$E"$(4LJ4``293,MID`)G,R`&X"-MUB/<-2TOC/;M&G;%*-^7'* M+.XBP')X5+.)O)(*%@$BM6[8R%>DGV/R]Q8E5.@*QCFE55@54-XG*7Q*50V^ MA`$Z9M1&TZC_`'I>*&BJME15*=(O-4TVKT4=T`.A7=%?YQB.2;]!7$ZRS$I8 M;'K_`"CGY^M:GF`M$C+>DME)ZQ$B^4YW- MYM!R$/.ZUI6PNGLNI)I6#4#TA2;C6ZC)DT"%8#0Z318L(I)1H9453FO0",`)#0A`EA/$$S)QE M*1;W+%97:8F+AX_<=MQ-%@H].\>8G8:Q6)><([(W(FC)2\Y3[1(-TV`H"9$6 M*C,_DJ;S,Y@\PK'6:HZB3-Z1?K[GMPK,A$1"J(HUEY^*96>=:0"S5`&Q MDF#YFJFW'Q243[%$$;M4'@J=*V%':`0>G.'^AL2Z!37=WJM6TB786I"DD#T3 M-N8&S`@@9$0^?I)#_`Z((0':\0GMA_#DXOD%NV+,V;)TS>,\:F:)!#,FOY*RY_;9ML]:%3$B1F3IH4"&'R*8>PAN:=2U.;*%GVI_(1#=74#M;I"+E4 M,)`Q#90)])4A1\!$1<3WH.XHVJ;E[+9]AY2V*QS\B\F)V>G+[0969F9:07.Z M?RR$@]_3B+Q4)`2EIL)&6!^>(DY]WEH><6 MZ[75:G%$DDK022`:Z:2\@I"XRB;IZX=HI MRKVN5^L1;G\/16*W1.#,BHHI%^4RBGDH9M<6%K*@@)!V#*)E2L*IF$,+J''5 M)GVED%1F2<2`D83D,,@(/W7B%$?_U8\.*?%/8N8^Q5[%\8KZDK/2RA'4W-NB M.$ZS1ZPFX00E+A<)-%!<(R!BP7+W$"G7MBMD1&=WNV/IV&R2K:VDQ8J-GK?>=UL"S2(RC!F3IYV5A&#T961 M8%.S;MY$7,FF]JD72MO5S-6ZM*=.#8D5E$SAW38Q6Y[1$@>T2DA)%*+O%=S# M=OBWE!(29-)`*U-XX=VV//<]HB0.)*9)E#)N&HL-6?Q%U/0FO,2)S9R2KYJW ME&2W&GU'\=S1IC,F%>J*MNE,\1UE[#-D$D#.IB3AVR)+;Z9RF2L6JT!HJS=?/;6=Z@"IQ70M23")06S0D:LG6^-_&*F(SS@#MFU MKT"!-R4U>0*<1(D*47:X97)8MX43`9->*IC-\DIV$K@1*406+I5*!775RM`Q MDD]T@=8.L\0I9'"%JZ-:OI;I=EE`QTH/G5\7`_'V*4[U,!$Q>YBAW$-OQ2E" M;5(ZH=`1XG"@^*%/QZUB;%O?6.*0CQ.*0?%$FGIC@\GB/9KQR1@="M=NGFZ^ MJ$CSML[:P=0?''$]**Z5":EKM^TQ&Y&GF9+Y(-)0ZGB4Q2!W,##S0NI58*\J M82E,D^E,CMIV!,I_C>&(OSJY6+Y:N'>4R$-3;GVYJ^M1+`)ET]KPQ?LZIB*' MAN?*;<)7CUE"^D0U63N3MK9JO#J0!G2S19TRF95)H_,P.@BN=6329B<6R0E\ M55O$HB`#WZ((PKCR'0@MZX^XW!136>9;,PMLS*68CPP)0$1%TBSVNJ.&2:1# MD?'M*]3>ID\Q*4$6ZA@$1``Z((\:%I.UEV`,KR&L9;*&99M%Z!,2FD6>V0`% M"6M$]7$&$:G6*M9?G%,87Y#F5!+]/L'?MT009=*T:\Y7Q_MNEV*#JCV^U"HO M9M]`PLO,+5!Q+-S^*;1I,/HIC,FCCE.7R4.T(J`]^Q!^G<@C24[3]7BM#@,W MW"GT.#>WF)GI&B6?-;5/V2`D9&KIM75L,RPT31IJF" M!+PPS"&CH20B!7AY`B\8S"1<)#(RC11,H))"FN<@A>-)T-EG667/3WC%XY:U M.ES%M+#G24:24@M'Q2T@R@R-U2_*C*2;HJ;4B1B^8+J`7MW^G1!&/C]\=Z1G M\-99:.:PMD(XFJ[-8&[U";D:K<89LZ6206=-(^QP[E-!8Q"BL@!%` M#L/:"ZTVG.K.\C6\4LWONK4\&C9=1PD9#.]0N&?M7HJ*D3,"TFUK) M'*A.WBFHJ)0$0`!$@A4>B"&>M=UV&?M5MDZ=G%2L66T/6QR2RQ[6QS"^Q"JQ MFXN`L%S95MK"KP",-#JR@R!&2[HKMW#H&[0%!G+259P#FH6Z?(1//U'[W38-&-FUUD,XJQ\>V$'ZE:DJ?/3<[<\^;_@\K/02^JL%H M1O!LBOT(D8][]FX.$9,.$FQQ4`14`@C><@M*W3-'U5>9[5LFGZM9K30J"16Y MVJXPM@;VV]VDE::K&90=2F8X:ZS%\U445!P+GM\H`B/B3R((,>FZ)I6:XHC; MGL!1G^GJ3F>58T(UG)_]@PG+_I%9H3=0LXK!HV$8IB6R$<'/]A\PBF(`F/T[ MD$&/-W.]+OI(->A,ABHTK1(8A3-[1W^[VZ((:J]Y"V%/A_"\DXZGL9&SS664N^M:. M63508+RUM:PBQ()*641^4J)'$O\`&18Y`[]@$P!]>B"#;4-XB[[9>X;4Z)./J!$0DG>9W1K%.P,*E+65!R_@Z7")UZ#F7Z\VM#-R/7 M3I4I6K1!TW``6.$V:>NSC\YI^/4R5TS0'31K* MWVQL?V7C+QJUL(0J(>#VU3U=@(6O19ESA'QZLBDW9-0.;R7=JK*N'FYW5^^5 MP=JW@VSDD&92@="022=IEB=PR?[S>ZGF&O#U8\&V`9)3B4H3T`$DG:93)W#* M+'E/BWLEY)S4A.2?%>;#Q7KBU+MZHJ5F9HT=5G]Z^V;C1J9-MD^P! M,P%3B)HPF%0[HR@$$LEMU78*!"6TW-/$Z7@3[VAMM2AP4M2>$22U5G+UM2`F MY#$8G2\">!T-MJ(/JJ6I/"(V;QZN/97H$BM.7SAU(;59%&_V;>R\B>:T#H4O M%,B$,5NPAE*)KF0(L6#,1[HMS$513_1`OA^;T_-\PV!I)0S=0RWN:84D3WG4 MA>)VY8Q)6.9^6Z=.AB[]RWN:IM`/3J0LGIG,P0G7J@]LOV)(J"XA8)58U(1, M@2++Q&EI9$1[@7PN-SLEJO1C)`/YICRAC]P`>XF`!ZW#F3EN94JZ.J41+'O@ M/R4I"?%"D/$:(B(B(CL^'#W$1[B(_P#U M&[B(CTI_F_E[_G_^MS]2%@Y[Y7`PKE?Y;GZL?G_L3>T'_P!.\;_YSX=_^1NC M^;^7O^?_`.MS]2,_SYRQ_P`]7^6Y^K$@?JT]37/+C7SNPK:]EQEC5,WI:NAG MLD^CIV56!1@6>RB]5F+\8BMW66FG?W,U--D?U+=3P!3S-XD*8P,W,',MEK;/ M64M-6:GUA,AH6)R4DYE(&0VF([S5S98KI8JVAHJLJJ5E$AH6)Z7$*.)2!D#M MBX[U5D5!"$;_`$J=O4%GL=!Q19C\)V_'K3-MCKLD4TJQ6[O&2EA>J@^<-TW" M3.,04.9$GFJJ`>)"',(%$@AJF5.F7'_ M`#?CQK6:YI8'QB/`75>6NW755TJU2*HY1&1(*R9?C5,0@C?%X\4ZO-X_E M%8BY3[EH8'4Y6[?KLG-,?M".#/DA9,;,Q4^11(J1_G[$,8Q3@4C.R$%!3?L= M_>GFN=9!)79Q>[[H][RG4$)RG-*'5WVJ3+^WR(:BQF;"PM+-.FW"=>J^$='R M/XE'D1(CV7,=,A&(4_D#GFA:A5,WS2&F'\2UEKY5973-"@20#9Y7H>@MW%W9 MOXJ%L*4NQ>N9[0*]$M2-5&C]L5NNK\Y#)%-W((\8'F-WR"S:Q69VRV70:I:9 MR)TJ`OMG&HMY->R6&/-#WBN.XNIQE;8LU&KRN-9(JB,8B@N,HB,1&UI5#U*Q7FPI,^/SB/VE>[`MG/+#.YFI52O1] M`3L2#NN*:6NG;8R^6!:IU;M'2<"YBY-G,BW,")?A6`4R"':\F*3*:1QYVVBP M,.E/V.T9==XJK1*RC)`'=K6K[\:L"+F26;,63M"PD;*(+JJ)%06(53S)X^0$ M$*E"0S>!J\17H1FRA&L+`L(:(8-6J2<=$(1T>DR8-&S)L*2)&3!-$A"))B4H M)D`I>P=NB"(^J+0]0ZO+Y/+MWC0\S#-W\,?]:JX*LD)%2"'8[U4+%QR4/!@=W6XAV4"N72*:GZ'EW, M'1`(*_&^H5:IR]F)6>(LOQM+(1K$SZ9?.06C5S2C/)>'`JW'*\3^?6Z4 MG/A))?(Y4D6]"=PR37L9XD$XH<40(!C%(SA#DJ'3=3J''N[5V!C()CIZUJY! M3U2C;4HA(5UXK;-@T2VU`DT>,1Z"A/E;NBHK_&JDL4@HK)'.00;5BB=%4A0[F,DH4H?0.XF*(`'<>P!W M$>B"&6Q^3W]'@OG^0*P!BZ+"Y+DE:DZ[^(Q(F;3=:"IA-LADBOQAU19?AJW= M0C@R1_#\PQNX=\1G;'UJ^(W.C\N5[E"-2+8E-4?4+$GW>LR'J&IZ+9LV=VV% M9QRCG\0/#VY>HJ3H'33,BG).GWF)/E3`V8(W%C4TK&]:T6XU+'[3LE:V-O3Y M`4Z7-TF*EJM>JO`EJ!F<\C=;+66Y*I,P<C6("1G';"-`C90Y623ITLBDL +*?RG$@&$`((__]D_ ` end
-----END PRIVACY-ENHANCED MESSAGE-----